Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen Bio – March 18, 2026
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
Tevogen Bio – March 13, 2026
Tevogen Receives $1 Million to Accelerate AI Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
Tevogen Bio – August 7, 2025
Tevogen Receives $1 Million to Accelerate AI Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
Tevogen Bio – August 7, 2025
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Tevogen Bio – August 5, 2025
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
Tevogen Bio – July 18, 2025
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch
Tevogen Bio – July 16, 2025
Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
Tevogen Bio – July 14, 2025
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
Tevogen Bio – May 30, 2025
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Tevogen Bio – March 7, 2025
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
Tevogen Bio – January 24, 2025
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
Tevogen Bio – January 23, 2025
